Evidence map›Paper›PMID 40851704›Full record

ArticleCureus2025

Population Pharmacokinetic-Pharmacogenetic (PopPK-PGx) Model of Efavirenz in HIV-1-Infected Patients.

Katarina Vucicevic, Danica Michalickova, Bozana Obradovic, Jovan Ranin, Djordje Jevtovic, Relja Lukic, Andrew Owen, Gordana Dragovic

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Katarina VucicevicDepartment of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, Belgrade, SRB.
Danica MichalickovaDepartment of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, CZE.
Bozana ObradovicDepartment of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, SRB.
Jovan RaninDepartment of Infectious Diseases, Faculty of Medicine, Clinical Centre of Serbia, Clinic of Infectious and Tropical Diseases, University of Belgrade, Belgrade, SRB.
Djordje JevtovicDepartment of Infectious Diseases, Faculty of Medicine, Clinical Centre of Serbia, Clinic of Infectious and Tropical Diseases, University of Belgrade, Belgrade, SRB.
Relja LukicDepartment of Gynecology and Obstetrics, Obstetrics and Gynecology Clinic "Narodni Front, Faculty of Medicine, University of Belgrade, Belgrade, SRB.
Andrew OwenDepartment of Pharmacology and Therapeutics, Centre of Excellence in Long-Acting Therapeutics (CELT) Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, GBR.
Gordana DragovicDepartment of Pharmacology, Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Belgrade, Belgrade, SRB.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objectives Efavirenz (EFV) exhibits substantial inter-patient pharmacokinetics (PK) variability. Polymorphisms in genes involved in EFV metabolism have been associated with EFV exposure, but they have not been fully implemented to inform dosing in treatment guidelines. This work aimed to develop a population pharmacokinetic-pharmacogenetic (PopPK-PGx) model of EFV in human immunodeficiency virus type 1 (HIV-1)-positive patients, and to simultaneously explore the influence of CYP2B6

Indexed as

adherencecyp2b6efavirenzgeneticsnonmempoppk

Identifiers

PMID40851704
PMCPMC12370162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.